Navigation Links
VIRxSYS Publishes New Study on RNA Therapy
Date:4/6/2009

d an immune response. The technology used to perform the albumin splicing process is owned by VIRxSYS and is known as spliceosomal mediated RNA trans-splicing, or SMaRT(TM). VIRxSYS now has 39 publications in top tier journals showing the effectiveness of SMaRT(TM) in a broad variety of applications. The company expects to begin testing this technology in human trials in the second half of 2010.

The study was headed by Madaiah Puttaraju, Ph.D., of VIRxSYS. The full citation for the study is: Wang J, Mansfield SG, Cote CA, Jiang PD, Weng K, Amar MJ, Brewer BH Jr, Remaley AT, McGarrity GJ, Garcia-Blanco MA, Puttaraju M. Trans-splicing into highly abundant albumin transcripts for production of therapeutic proteins in vivo. Mol Ther. 2009; 17(2):343-51; doi:10.1038/mt.2008.260. Drs. Amar, Brewer and Remaley were collaborators at the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health. Part of these studies was performed under a cooperative research and development agreement (CRADA) between VIRxSYS and the NHLBI.

About VIRxSYS

Founded in 1998, VIRxSYS is a private biotechnology company that focuses on the development of a novel lentiviral gene delivery platform technology for the treatment of serious diseases. The Company has exclusively licensed its patented, proprietary lentiviral technology platform from The Johns Hopkins University (JHU) in Baltimore, Maryland where the original research was conducted. The Company obtained its SMaRT(TM) technology from Intronn Inc. More information regarding VIRxSYS can be found at www.virxsys.com.

    Contact: Russell LaMontagne
    Phone:   212-255-5340
    E-mail:  russell@corinthgroup.com


'/>"/>
SOURCE VIRxSYS Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. VIRxSYS and Lentigen Announce Litigation Settlement
2. VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial
3. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
4. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
5. Consortium publishes Phase II map of human genetic variation
6. The Lancet Publishes Vasogens ACCLAIM Results
7. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
8. The Lancet Publishes Results From Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
9. Springer publishes anthology with the Nanoethics Group
10. The Scientific Business of Thomson Reuters Publishes Its 2008 Liquent Regulatory Affairs Trends Survey Results
11. Waters Publishes Rapid and Specific Method of Detection for Melamine in Infant Formula and Liquid Milk, in Support of Chinas Ministry of Science and Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Aug. 22, 2014 Research and Markets ... and China Gel Permeation Chromatography (GPC) Industry Report 2014" ... Global and China Gel Permeation Chromatography (GPC) Industry Report ... state of the global gel permeation chromatography industry with ... provides a basic overview of the industry including definitions, ...
(Date:8/22/2014)... 2014 The identification of protein-coding ... be accelerated by exome sequencing. Built on Roche ... custom SeqCap EZ Developer system has been a ... will additionally present how he achieved coverage statistics ... and mouse exome kits. With over 236,000 SNPs ...
(Date:8/21/2014)... group at the Institute for Molecular Medicine Finland ... has developed a novel "man and machine" decision ... diagnostic aid was described in PLOS One ... is based on computer vision algorithms similar to ... visualization of only the diagnostically most relevant areas. ...
(Date:8/21/2014)... 2014 His Majesty Willem-Alexander, King of ... Court of His Majesty Willem-Alexander, King of the Netherlands, ... Opening of POET-DSM Advanced Biofuels’ Project LIBERTY cellulosic ethanol ... The King will take part in the Grand Opening ... 11 a.m.-12:20 p.m. and tour the plant. POET-DSM is ...
Breaking Biology Technology:Global and China Gel Permeation Chromatography (GPC) Industry Report 2014 2Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2A novel 'man and machine' decision support system makes malaria diagnostics more effective 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3
... Sept. 6, 2011 The Immune Deficiency Foundation (IDF) ... continuing education (CE) course for  nurses. The goal of ... nurses by providing an educational update on primary immunodeficiency ... is the national patient organization dedicated to improving the ...
... 6, 2011 Auxilium Pharmaceuticals, Inc. (NASDAQ: ... safety update following 17 months of post-approval use in ... Dupuytren,s contracture patients with a palpable cord.  After approximately ... U.S., there was no clinically meaningful change in the ...
... Genprex, Inc., formerly known as Convergen LifeSciences, Inc., announced today ... will be branded as Oncoprex™ .   ... oncology sector in recognition of our advancing development programs.  We ... to unlock the unrealized potential of a growing list of ...
Cached Biology Technology:Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy 2Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy 3Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update 2Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update 3Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update 4Genprex Announces New Branding 2
(Date:8/22/2014)... , August 22, 2014 ... ) has announced the addition of ... 2014-2018"  report to their offering.  ... ,Biometrics is a technology that helps ... on their physical or behavioral features. ...
(Date:8/22/2014)... RIVERSIDE, Calif. Thomson Reuters , a leading ... five researchers at the University of California, Riverside in ... brightest minds of our times." , To generate the ... (2002-2012) to identify researchers whose published work has had ... included among some 3,200 individuals who published the greatest ...
(Date:8/22/2014)... the 29th Annual International Papillomavirus Conference shows that ... combats three types of human papillomavirus, including the ... cancer. , When tested in several cultured human ... HPV-18 and HPV-11 cells, according to Louise T. ... the findings at the Seattle conference. The National ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... Inc. (Nasdaq: AWRE ), a leading supplier of ... to discuss the company,s operating results for the fourth quarter ... 5:00 p.m. Eastern Time. CEO Michael Tzannes and CFO Rick ... webcast by Thomson and can be accessed on the Investor ...
... the potentially fatal hepatitis C virus has banked its ... inability to infect animals other than humans and chimpanzees ... animal model for the disease. But now, in a ... online issue of Nature , Rockefeller University scientists ...
... . , Lack of sleep is a ... the day poses a very real and dangerous problem. ... at McGill University demonstrates interestingly, that sleep-wake states are ... melanin-concentrating hormone (MCH) neurons and orexin (Orx) neurons, which ...
Cached Biology News:Aware Announces Q4 and FY2008 Earnings Conference Call 2Discovery could lead to a new animal model for hepatitis C 2What happens when we sleep 2
Bovine Brain Microvascular Endothelial Cells (BBMVEC) (>500,000 cells)...
... ,• Eliminates nonspecific products due to ... specificity allows extension through DNA regions which ... Leaves an 'A' overhang ,TEMPase II ... DNA Polymerase that remains inactive at ...
Rabbit anti-CRSP1 (TRAP220), Polyclonal Antibody, Unconjugated Applications: Immunohistochemistry - 1:100 - 1:500...
... pleased to offer the ATTO-TAG series ... of primary amines. Developed by Novotny ... ATTO-TAG reagents are similar to the ... and anthracene-2,3-dicarboxaldehyde, all of which are ...
Biology Products: